AstraZeneca: Eplontersen Demonstrated Sustained Benefit in Phase III Trial for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy Through 66 Weeks
March 28, 2023
March 28, 2023
WILMINGTON, Delaware, March 28 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022./1
At 66 weeks, patients treated with eplontersen contin . . .
Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022./1
At 66 weeks, patients treated with eplontersen contin . . .